Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin

G. Conforti, A. M. Codegoni, E. Scanziani, E. Dolfini, T. Dasdia, M. Calza, M. Caniatti, M. Broggini

Research output: Contribution to journalArticle

Abstract

We selected two clones, isolated from the human colocarcinoma cell line LoVo, showing a sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to the drug. For comparison we used the parental cell line LoVo WT and LoVo/DX made resistant pharmacologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo/DX. This increase in mRNA levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immunefluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5 and 7, there were respectively 8.6% and 71% vimentin-positive cells, although the two clones showed similar expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels. Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be considered as a marker of resistance in these cells but does not give rise to a resistant phenotype by itself.

Original languageEnglish
Pages (from-to)505-511
Number of pages7
JournalBritish Journal of Cancer
Volume71
Issue number3
Publication statusPublished - 1995

Fingerprint

Vimentin
Doxorubicin
Clone Cells
Cell Line
Messenger RNA
MDR Genes
Southern Blotting
Pharmaceutical Preparations
Northern Blotting
Glycoproteins
Complementary DNA
Immunohistochemistry
Breast Neoplasms
Phenotype
Gene Expression
DNA

Keywords

  • Doxorubicin
  • Drug resistance
  • Human cell line
  • Intermediate filaments

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. / Conforti, G.; Codegoni, A. M.; Scanziani, E.; Dolfini, E.; Dasdia, T.; Calza, M.; Caniatti, M.; Broggini, M.

In: British Journal of Cancer, Vol. 71, No. 3, 1995, p. 505-511.

Research output: Contribution to journalArticle

Conforti, G, Codegoni, AM, Scanziani, E, Dolfini, E, Dasdia, T, Calza, M, Caniatti, M & Broggini, M 1995, 'Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin', British Journal of Cancer, vol. 71, no. 3, pp. 505-511.
Conforti, G. ; Codegoni, A. M. ; Scanziani, E. ; Dolfini, E. ; Dasdia, T. ; Calza, M. ; Caniatti, M. ; Broggini, M. / Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. In: British Journal of Cancer. 1995 ; Vol. 71, No. 3. pp. 505-511.
@article{369c1fcae7054c93abdb6c8db57fe5b0,
title = "Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin",
abstract = "We selected two clones, isolated from the human colocarcinoma cell line LoVo, showing a sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to the drug. For comparison we used the parental cell line LoVo WT and LoVo/DX made resistant pharmacologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo/DX. This increase in mRNA levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immunefluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5 and 7, there were respectively 8.6{\%} and 71{\%} vimentin-positive cells, although the two clones showed similar expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels. Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be considered as a marker of resistance in these cells but does not give rise to a resistant phenotype by itself.",
keywords = "Doxorubicin, Drug resistance, Human cell line, Intermediate filaments",
author = "G. Conforti and Codegoni, {A. M.} and E. Scanziani and E. Dolfini and T. Dasdia and M. Calza and M. Caniatti and M. Broggini",
year = "1995",
language = "English",
volume = "71",
pages = "505--511",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin

AU - Conforti, G.

AU - Codegoni, A. M.

AU - Scanziani, E.

AU - Dolfini, E.

AU - Dasdia, T.

AU - Calza, M.

AU - Caniatti, M.

AU - Broggini, M.

PY - 1995

Y1 - 1995

N2 - We selected two clones, isolated from the human colocarcinoma cell line LoVo, showing a sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to the drug. For comparison we used the parental cell line LoVo WT and LoVo/DX made resistant pharmacologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo/DX. This increase in mRNA levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immunefluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5 and 7, there were respectively 8.6% and 71% vimentin-positive cells, although the two clones showed similar expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels. Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be considered as a marker of resistance in these cells but does not give rise to a resistant phenotype by itself.

AB - We selected two clones, isolated from the human colocarcinoma cell line LoVo, showing a sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to the drug. For comparison we used the parental cell line LoVo WT and LoVo/DX made resistant pharmacologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo/DX. This increase in mRNA levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immunefluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5 and 7, there were respectively 8.6% and 71% vimentin-positive cells, although the two clones showed similar expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels. Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be considered as a marker of resistance in these cells but does not give rise to a resistant phenotype by itself.

KW - Doxorubicin

KW - Drug resistance

KW - Human cell line

KW - Intermediate filaments

UR - http://www.scopus.com/inward/record.url?scp=0028901404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028901404&partnerID=8YFLogxK

M3 - Article

C2 - 7880731

AN - SCOPUS:0028901404

VL - 71

SP - 505

EP - 511

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -